US asset owners seeking diversification and returns in a low-yield environment will find it hard to disregard Chinese deals such as the mega Chinese IPO, despite political tensions.
The city's exchange operator will accept applications from pre-revenue biotech companies and issuers with dual-class shares from next Monday, despite lingering concerns.
Hong Kong's exchange proposes allowing pre-revenue innovative companies with dual-class structures to list in the city, raising concerns about investor protection.
Instead of a joint SFC-HKEx committee to rule on listings and develop policy, itself a compromise, investors are left with a consultative panel that lacks any formal powers.
The Hong Kong Investment Funds Association is firmly against stock exchange proposals to allow dual-class share structures. But asset managers are divided on the issue.
The Chinese fintech giant's chief executive, Eric Jing, sets out his big idea ahead of an eagerly awaited IPO, tipped for next year.